JERUSALEM, Dec. 5, 2024
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)
("Scinai" or the "Company"), a biopharmaceutical company
specializing in the development of inflammation and immunology
(I&I) biological products and offering CDMO services through
its Scinai Bioservices unit, announced today the appointment of
Prof. Michael Schön to its Scientific Advisory Board (SAB).
Prof. Michael Schön is a distinguished Professor and Director of
the Department of Dermatology, Venereology, and Allergology at
the University Medical Center Göttingen. He also serves as Vice
Dean and Deputy Director for Research and Teaching and is the
former director of the Lower Saxony Institute of Occupational
Dermatology. Prof. Schön has been recognized with numerous awards
for his groundbreaking research on immune reactions in
inflammation. From 2011 to 2024, he was the Editor-in-Chief of the
Journal of the German Dermatological Society. Currently, he holds
the position of Secretary General and Vice President of the
European Dermatology Forum (EDF).
Prof. Schön earned his MD in Medicine from the University of
Ulm, Germany. He has worked at the
Free University of Berlin,
Harvard Medical School and the
universities of Düsseldorf and Magdeburg. Before his appointment at
the University Medical Center Göttingen, he held a professorship in
Experimental Biomedicine at the University of Würzburg. Michael has
further qualifications in dermatopathology, allergology, immunology
and health economics.
Prof. Schön commented: "It is a great pleasure and honor for me
to be part of the advisory board for Scinai and to contribute to
the success of their highly innovative pipeline. In many areas of
chronic inflammatory skin diseases, but also in other organ systems
with immunologically mediated diseases, there is a significant
unmet medical need. In my view, Scinai's targeted immunological
therapeutic approaches have excellent potential to provide exciting
innovation in various areas of precision inflammation
medicine."
Amir Reichman, CEO of Scinai,
stated: "We are thrilled to welcome Prof. Schön, a world-class
expert in dermatology, particularly in psoriasis and atopic
dermatitis, to our Scientific Advisory Board. Michael's extensive
experience as a dermatologist, having treated thousands of
patients, and as a researcher with over 440 scientific publications
in top-rated journals, along with his proven track record in drug
development and clinical research, will be invaluable to Scinai.
His insights will be crucial as we advance our pipeline of
innovative I&I biological products. Additionally, I would like
to congratulate Dr. Jonathan Sadeh,
a member of our Scientific Advisory Board, on his recent
appointment as Chief Scientific Officer and Chief Medical Officer
of Bausch Health. We wish Jonathan great success in his new role.
These two recent appointments to our Scientific Advisory
Board are a testament to the high caliber of talent advising our
R&D team and board of directors."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked pipeline of nanosized VHH antibodies
(nanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical cGMP manufacturing, and
pre-clinical and clinical trial design and execution services for
early stage biotech drug development projects.
Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, are forward-looking statements.
Examples of such statements include, but are not limited to, the
potential of Scinai's NanoAb program and the advancement of its
pipeline of innovative I&I biological products. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and uncertainties include,
but are not limited to; the risk that the Company will not
successfully advance its pipeline of innovative I&I biological
products; the risk that the Company will otherwise be unable
to remain compliant with the continued listing requirements
of Nasdaq; a delay in the commencement and results of pre-clinical
and clinical studies, including the Phase 1/2a study for psoriasis,
the risk of delay in, Scinai's inability to conduct, or the
unsuccessful results of, its research and development activities,
including the contemplated in-vivo studies and a clinical trial;
the risk that Scinai will not be successful in expanding its CDMO
business or in-license other NanoAbs; the risk that Scinai may not
be able to secure additional capital on attractive terms, if at
all; the risk that the therapeutic and commercial potential of
NanoAbs will not be met or that Scinai will not be successful in
bringing the NanoAbs towards commercialization; the risk of a delay
in the preclinical and clinical trials data for NanoAbs, if any;
the risk that our business strategy may not be successful; Scinai's
ability to acquire rights to additional product opportunities;
Scinai's ability to enter into collaborations on terms acceptable
to Scinai or at all; timing of receipt of regulatory approval of
Scinai's manufacturing facility in Jerusalem, if at all or when required; the
risk that the manufacturing facility will not be able to be used
for a wide variety of applications and other vaccine and treatment
technologies; and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
Annual Report on Form 20-F filed with the Securities and Exchange
Commission ("SEC") on May 15, 2024,
and the Company's subsequent filings with the SEC. Scinai
undertakes no obligation to revise or update any forward-looking
statement for any reason.
Photo -
https://mma.prnewswire.com/media/2574354/Scinai_Immunotherapeutics.jpg
Logo -
https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/prof-michael-schon-director-of-dermatology-and-venereology-at-the-university-medical-center-gottingen-germany-umg-joins-scinai-immunotherapeutics-scientific-advisory-board-302323843.html
SOURCE Scinai Immunotherapeutics Ltd.